J Pathol Transl Med.  2018 May;52(3):198-201. 10.4132/jptm.2017.08.01.

Secretory Carcinoma Arising in a Fibroadenoma: A Brief Case Report

• Lim S
• Shim MK
• Cho EY
• Cho SY

• KMID: 2412934
• DOI: http://doi.org/10.4132/jptm.2017.08.01

Abstract

No abstract available.

MeSH Terms

Fibroadenoma*

Figure

• 

  Fig. 1. Microscopic findings. (A) Low power field image shows fibrous septa within the tumor and peripheral hypocellular area (thick arrows). (B) Tumor shows solid or microcystic growth patterns within dense fibrous stroma. Cribriform tumor nests contain extracellular secretory material (thin arrows). Tumor cells have abundant, vacuolated cytoplasm. (C) Periodic acid Schiff staining highlights intra-and extracellular secretory material. (D) Tumor cells are diffusely positive for S-100 protein. (E) At the periphery of cellular tumor (left upper), hypocellular myxoid area is present (right lower). (F) Peripheral myxoid area shows mixture of bland tubules (arrows) and irregular tumor nests. (G) Tumor cells are positive for S-100 protein, while bland tubules are negative. (H) p63 staining highlights the presence of myoepithelial cells in the myxoid area. A few tumor cells express p63. (I) Ductal carcinoma in situ (DCIS) is noted in (left side) and outside the boundary of fibroadenoma. (J) DCIS also shows intracellular and extracellular secretory material.

Reference

1. Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012; 21:350–3.

2. Diaz NM, Palmer JO, McDivitt RW. Carcinoma arising within fibroadenomas of the breast: a clinicopathologic study of 105 patients. Am J Clin Pathol. 1991; 95:614–22.

3. Wu YT, Chen ST, Chen CJ, et al. Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy. World J Surg Oncol. 2014; 12:335.

4. Chintamani , Khandelwal R, Tandon M, et al. Carcinoma developing in a fibroadenoma in a woman with a family history of breast cancer: a case report and review of literature. Cases J. 2009; 2:9348.

5. McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA. 1966; 195:388–90.

6. Tavassoli FA, Norris HJ. Secretory carcinoma of the breast. Cancer. 1980; 45:2404–13.

7. Laé M, Fréneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol. 2009; 22:291–8.

8. Jacob JD, Hodge C, Franko J, Pezzi CM, Goldman CD, Klimberg VS. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. J Surg Oncol. 2016; 113:721–5.

9. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002; 2:367–76.

10. Vasudev P, Onuma K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med. 2011; 135:1606–10.